NCT02001025

Brief Summary

The biodegradable ABSORB scaffold is characterized by a greater strut thickness, but it has a greater flexibility compared to the XIENCE stent. Due to its fragility the inflating pressure of the ABSORB scaffold is limited and suitable lesions have to be well prepared. This study assesses the incidence of malapposed stent-struts, and the frequency of stent-underexpansion and edge dissection after ABSORB implantation compared to the XIENCE stent.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2013

Completed
26 days until next milestone

First Submitted

Initial submission to the registry

November 27, 2013

Completed
7 days until next milestone

First Posted

Study publicly available on registry

December 4, 2013

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2014

Completed
Last Updated

December 4, 2013

Status Verified

November 1, 2013

Enrollment Period

1.1 years

First QC Date

November 27, 2013

Last Update Submit

November 27, 2013

Conditions

Keywords

coronary vesselscoronary stenosispercutaneous transluminal angioplastystentsdrug-eluting stentsbioresorbable scaffoldsoptical coherence tomography

Outcome Measures

Primary Outcomes (1)

  • adverse post-stenting results

    Malapposition, underexpansion and edge dissections assessed with Optical Coherence Tomography (OCT)

    1 year

Study Arms (2)

Absorb scaffold

Bioresorbable vascular scaffold implanted in coronary arteries, which are completely resorbed over a period of approximately two years

Device: Absorb scaffold

Xience stent

Second generation drug-eluting stent to treat coronary artery lesions

Device: Xience stent

Interventions

Absorb scaffold
Xience stent

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with coronary artery disease

You may qualify if:

  • age \< 55 years OR
  • lesion length \> 24mm OR
  • multiple lesions to be treated

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Medical University of Vienna

Vienna, Vienna, 1090, Austria

RECRUITING

MeSH Terms

Conditions

Coronary Stenosis

Condition Hierarchy (Ancestors)

Coronary DiseaseMyocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular Diseases

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

November 27, 2013

First Posted

December 4, 2013

Study Start

November 1, 2013

Primary Completion

December 1, 2014

Last Updated

December 4, 2013

Record last verified: 2013-11

Locations